Open access · US-GOV via ClinicalTrials.gov Clinical trial

Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD

Authors not listed

Vitreous -Retina- Macula Consultants of New York · 2006

Dysbiosis Human Randomized controlled trial

Abstract

The purpose of this study is to explore the combination of PDT with verteporfin at reduced and standard fluence rates, in conjunction with bevacizumab, in the treatment of subfoveal CNV of all subtypes with a high percentage of subretinal hemorrhage (hemorrhage \>50% of total lesion area). To assess the safety of bevacizumab in combination with verteporfin PDT (reduced fluence: 300 mW/cm2) as compared to bevacizumab in combination with verteporfin PDT (standard fluence: 600 mW/cm2) in patients whose neovascular CNV lesions containing \>50% blood.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-26 MST

Cite this

APA

Anonymous. (2006). Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD. <em>Vitreous -Retina- Macula Consultants of New York</em>. https://clinicaltrials.gov/study/NCT00403442

Vancouver

Anonymous. Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD. Vitreous -Retina- Macula Consultants of New York. 2006.

BibTeX

@misc{anon2006Bevaci, title = {Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD}, author = {Anonymous}, journal = {Vitreous -Retina- Macula Consultants of New York}, year = {2006}, }